Abstract
Jóźwiak et al. suggest that their study, “…provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.” The study is problematic, however, because it compares two groups that have been ascertained in entirely different ways: the “Standard” group after presentation with tuberous sclerosis complex and usually epilepsy and the “Preventive” group with suspected or proven tuberous sclerosis complex but without epilepsy.
Original language | English |
---|---|
Pages (from-to) | 100-101 |
Number of pages | 2 |
Journal | Pediatric Neurology |
Volume | 110 |
Early online date | 5 Apr 2020 |
DOIs | |
Publication status | Published - 1 Sept 2020 |
Bibliographical note
Acceptance date is provisional and based on date of publication.Keywords
- tuberous sclerosis complex
- vigabatrin
- antiepileptic drug treatment